Effect of Ketoconazole on the Pharmacokinetics of Maribavir in Healthy Adults
|
|
- Debra Norris
- 5 years ago
- Views:
Transcription
1 ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2008, p Vol. 52, No /08/$ doi: /aac Copyright 2008, American Society for Microbiology. All Rights Reserved. Effect of Ketoconazole on the Pharmacokinetics of Maribavir in Healthy Adults D. Ronald Goldwater, 1 Carolyn Dougherty, 2 Mary Schumacher, 2 and Stephen A. Villano 2 * PAREXEL International, Baltimore, Maryland, 1 and ViroPharma Incorporated, Exton, Pennsylvania 2 Received 24 July 2007/Returned for modification 24 September 2007/Accepted 23 February 2008 Maribavir, an oral antiviral drug with activity against cytomegalovirus, is currently undergoing studies to assess its efficacy and safety as cytomegalovirus prophylaxis following stem cell or solid organ transplantation. The main objective of this study was to assess the effects of oral, a potent inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme, on the pharmacokinetics of maribavir. This was an open-label crossover study with 20 healthy adults. Subjects were administered a single dose of maribavir at 400 mg. After a washout period, subjects received a single dose of at 400 mg followed by a single dose of maribavir. Blood samples were collected for each drug sequence, and pharmacokinetic parameters for maribavir and its principal metabolite, VP 44469, were determined. Safety was evaluated by physical examination, clinical laboratory testing, 12-lead electrocardiogram, and monitoring for adverse events. Ketoconazole moderately reduced the clearance of both maribavir and VP 44469; oral clearance values were 35% and 13% lower, respectively, for maribavir-plus- treatment than for maribavir alone. Based on the assumption of complete inhibition of CYP3A4 activity, CYP3A4 is responsible for 35% of the overall clearance of maribavir. Treatment was generally well tolerated. The most-common adverse event was dysgeusia (taste disturbance), reported by nine (47%) and seven (35%) subjects in the maribavir alone and maribavir-plus- groups, respectively. The pharmacokinetic findings, in combination with the acceptable tolerability within the maribavir and maribavir-plus- treatment groups, suggest that no dose adjustment of maribavir is necessary when coadministered with CYP3A4 inhibitors or substrates. * Corresponding author. Mailing address: ViroPharma Incorporated, 397 Eagleview Boulevard, Exton, PA Phone: (610) Fax: (610) stephen.villano@viropharma.com. Published ahead of print on 3 March Maribavir is an oral antiviral drug with activity against cytomegalovirus (CMV) that has a favorable preclinical (5, 6) and early clinical (9, 15, 16) efficacy and safety profile. Maribavir is currently undergoing phase III studies to assess its efficacy and safety as CMV prophylaxis following allogeneic stem cell or solid organ transplantation. Maribavir is a benzimidazole L- riboside compound that has a unique mechanism of action in that it inhibits UL97 kinase activity, which reduces both viral DNA assembly and egress of viral capsids from the nucleus of CMV-infected cells (3, 7, 8). Maribavir has demonstrated good in vitro activity against CMV isolates or strains that are resistant to current CMV drugs (ganciclovir, foscarnet, and cidofovir) (1, 2). In pharmacokinetic studies, maribavir was rapidly and reasonably well absorbed, with a bioavailability of at least 30% to 40% (15). Mean peak plasma concentrations were largely dose proportional and were achieved between 1 and 3 h after administration in healthy individuals and in patients with human immunodeficiency virus (HIV) infection (9, 15). Maribavir has a mean terminal elimination half-life (t 1/2 ) of approximately 5 h in plasma, and based on studies in animals, maribavir is eliminated mainly by biliary excretion (10, 15). This is consistent with recent data showing that maribavir pharmacokinetics are similar in healthy volunteers and in those with renal impairment (14). Maribavir also undergoes extensive metabolism. In healthy and HIV-infected subjects, 2% of the dose is excreted unchanged in the urine (10, 15). The predominant metabolite in urine is VP (10). This inactive N-dealkylated metabolite is mainly formed by cytochrome P450 3A4 (CYP3A4) (15). Knowledge of the metabolic route of elimination of maribavir is useful for predicting potential interactions with coadministered drugs. Findings from a study with healthy volunteers given a mixture of markers for CYP enzyme activity indicate that maribavir does not affect CYP1A2, CYP2C9, or CYP3A isoenzyme activity but may inhibit CYP2C19 and CYP2D6 activity (11). Although maribavir was shown not to affect CYP3A4 isoenzyme activity, it is unknown what effect compounds that inhibit this isozyme have on the pharmacokinetics of maribavir. The main objective of this study was to assess the effects of oral, a potent inhibitor of the CYP3A4 isoenzyme, on the pharmacokinetics of maribavir. MATERIALS AND METHODS Subjects. Men or women between the ages of 18 and 50 years were eligible for enrollment. Subjects were required to be nonsmokers and otherwise healthy as determined by medical history, physical examination, laboratory results, vital signs, and 12-lead electrocardiogram (ECG). Women of childbearing potential were to follow an acceptable method of birth control. Subjects agreed not to take any prescription or nonprescription medications (including estrogen- and/or progestin-containing products, histamine antagonists, proton pump inhibitors, herbal preparations, or vitamins) or receive vaccinations during the course of the study. Subjects were instructed to refrain from consuming Seville oranges, grapefruits (including grapefruit juice), or alcoholic beverages during the study. They were also instructed not to drink or eat caffeine- and theobromine-containing beverages and foods for 24 h before or after dosing in each treatment period. All subjects provided written informed consent, and the study was approved by the institutional review board at the participating site. Subjects were excluded from the study if they were pregnant or breast-feeding; chewed tobacco or used nicotine replacement devices within 6 months before the 1794
2 VOL. 52, 2008 EFFECT OF KETOCONAZOLE ON MARIBAVIR PHARMACOKINETICS 1795 screening visit; required treatment for alcohol or illicit drug abuse within 2 years; had taken any prescription or nonprescription drugs during the 3 months before the screening visit; had received an immunization during the 2 weeks before the screening visit; had a known intolerance to ; had known liver disease (e.g., hepatitis B or hepatitis C); had elevated aspartate aminotransferase or alanine aminotransferase levels at the time of screening; had known immune deficiency disease or were HIV positive; had participated in any other investigational drug study within 30 days of the screening visit; or had participated in any previous maribavir clinical trial. Study design. This was an open-label, random-sequence, two-way crossover study conducted from 16 November 2004 to 4 January To achieve a target of 16 subjects who completed the study, 20 adults (10 men and 10 women) were enrolled at the Baltimore Clinical Pharmacology Research Unit and were randomized in a 1:1 ratio to receive one of two sequences (5 men and 5 women per sequence) of maribavir alone and plus maribavir. For sequence 1, treatment period 1, single-dose maribavir at 400 mg (four 100-mg tablets; Viro- Pharma Incorporated, Exton, PA) was administered on day 1, followed by a full pharmacokinetic profile assessment over 24 h. After a 1-week washout period, treatment period 2 consisted of a single dose of at 400 mg (two 200-mg tablets; Janssen Pharmaceutica, Titusville, NJ) administered on day 8, followed 1 h later by a single dose of maribavir at 400 mg and subsequently another full pharmacokinetic profile assessment over 24 h. The order of the two treatments was reversed in sequence 2. Subjects fasted overnight on the day before drug administration in each treatment period and continued to fast for 4 h after the maribavir dose in each treatment period. All study drug doses were administered under the supervision of study personnel. Sample collection and analysis. For each sequence, blood samples for determination of maribavir and VP plasma concentrations (separate samples for each) were collected just before the maribavir dose and then 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16, and 24 h after the dose. A 24-hour urine sample was collected on day 1 and day 8 of each sequence for determination of maribavir and VP concentrations. Urine collection began with the first voided specimen following administration of maribavir, and the final specimen was collected at the end of the 24-hour period on each day. Blood samples for the determination of plasma concentrations were collected 2 and 24 h after the dose in both sequences, and an additional sample was collected before the dose of maribavir in sequence 2 (trough value). Plasma and urine assays for maribavir and VP and plasma assays for were performed by Tandem Laboratories (Salt Lake City, UT) using validated tandem liquid chromatography and mass spectrometric detection methods. Plasma and urine samples of maribavir and VP were processed by solid-phase extraction. The validated calibration range in plasma was 5 to 1,000 ng/ml for maribavir and VP 44469; the accuracy (percent bias) and precision (coefficient of variation) based on quality control samples for each analyte were 5.3% and 9.1%, respectively. In urine, the calibration range for maribavir and VP was 50 to 10,000 ng/ml, with an accuracy of 9.3% and a precision of 11.3%. Ketoconazole samples were prepared by automated protein precipitation extraction. The validated calibration range was 50 to 5,000 ng/ml; accuracy was 9.3%. Pharmacokinetic endpoints and analyses. The primary pharmacokinetic parameters determined were area under the plasma concentration versus time curve (AUC 0-t and AUC 0- ), maximum plasma concentration (C max ), time to C max (t max ), terminal elimination rate constant ( z ), t 1/2, oral clearance (CL/F), terminal phase volume of distribution/bioavailability (V z /F), amount excreted in urine (Ae), and renal clearance (CL R ). The AUC 0-t was calculated as the AUC from time zero to the time of the last measurable concentration, calculated by the log-linear trapezoidal method. The AUC 0- was calculated as the sum of AUC 0-t plus the ratio of the last measurable plasma concentration to the z. Oral clearance was calculated as dose/auc 0-. The z was calculated by linear regression of concentration values in the apparent log-linear terminal elimination phase. The t 1/2 was calculated as 0.693/ z, the V z /F as dose/( z AUC 0- ), and CL R as Ae/AUC Nominal sampling times were used in the calculations, and WinNonlin Professional (version 2.1; Pharsight Corporation, Cary, NC) was used for the pharmacokinetic analyses. Safety assessments and endpoints. Safety was evaluated by physical examination, clinical laboratory testing (hematology, clinical chemistry, and urinalysis), vital sign measurement, 12-lead ECG, and monitoring for adverse events. Clinical laboratory testing was performed on the day before dosing and the day after dosing in both sequences. Liver function tests were performed at the 15-day follow-up visit. ECGs were performed on the day before dosing for treatment period 1 and at 2 and 4 h after dosing. ECG data included PR, QRS, QT, and QT c intervals and heart rate. All adverse events were recorded by the study Characteristic TABLE 1. Subject demographics investigator, who also assessed the severity and potential relationship to the study drug for each event. Statistical analyses. Based on an intrasubject coefficient of variation of 35%, a total of 16 subjects would have 90% power to show that the 90% confidence interval (CI) of the ratio of the geometric mean of the two treatment groups was within a range of 0.7 to The data analysis for pharmacokinetics and safety was generated using SAS/STAT software, version 8, of the SAS System for Windows (SAS Institute, Cary, NC). Data underwent natural logarithmic transformation before the analysis. An analysis of variance (ANOVA) was conducted on all parameters (except t max ) for a two-period crossover design fitting the terms for treatment, sequence, and subject within sequence. The ranked values of t max were analyzed with the ANOVA model. Estimates were calculated for the difference between the treatment least-squares means and their standard errors. These results were retransformed using antilogarithms to obtain the ratio of geometric means for maribavir plus to those for maribavir alone. Adverse events were summarized based on their incidence rates; no statistical analyses were performed. RESULTS Value for all enrolled subjects (n 20) Mean age yr (SD)...30 (9.3) Men n (%)...10 (50) Mean wt kg (SD) Men...80 (12.5) Women...71 (17.0) Race n (%) White... 9 (45) Black...11 (55) Patient disposition and demographics. Of the 20 subjects enrolled, 19 (95%) completed the study. One patient withdrew from the study after experiencing an adverse event (vomiting). Demographics for the 20 enrolled subjects are provided in Table 1. The mean age of the subjects was 30 years, and 50% were men. Pharmacokinetics. Mean standard deviation plasma concentrations of at 2 and 24 h after 400-mg administration were 6,149 2,423 and ng/ml, respectively. These values were comparable to those reported elsewhere in healthy volunteers (4). Plots for the mean plasma maribavir and VP concentrations over time are shown in Fig. 1. Mean maribavir plasma concentrations over time were higher with concomitant administration than with maribavir alone. Mean VP plasma concentrations following concomitant administration were lower for the initial 8 h and higher after 12 to 24 h than with maribavir alone. Summaries of pharmacokinetic results for maribavir and VP are presented in Tables 2 and 3, respectively. Values for maribavir C max, AUC, Ae, and t 1/2 were higher, and CL/F values were lower, for maribavir plus than for maribavir alone (Table 2). The test for treatment effects for t max was not statistically significant (P 0.536). The CL/F value, based on the ratio of geometric means, was 35% lower for maribavir-plus- treatment than for maribavir alone. Similarly, VP C max and z were lower, and t 1/2 values were higher, for maribavir plus than for mariba-
3 1796 GOLDWATER ET AL. ANTIMICROB. AGENTS CHEMOTHER. TABLE 3. Summary of VP pharmacokinetic parameters Parameter a Value for: Ratio of geometric means (95% CI) c t max (h) 2.5 (0.9) 5.5 (2.7) Different b C max ( g/ml) 1.6 (0.4) 1.0 (0.5) 0.60 ( ) z (1/h) (0.031) (0.030) 0.62 ( ) t 1/2 (h) 6.83 (1.7) 11.8 (5.5) 1.62 ( ) AUC 0 t ( g h/ml) 15.6 (3.2) 14.7 (4.1) 0.93 ( ) AUC 0 ( g h/ml) 17.4 (3.5) 20.5 (5.5) 1.15 ( ) V z /F (liters) 235 (78) 342 (141) 1.40 ( ) CL/F (liters/h) 23.8 (4.6) 21.1 (6.4) 0.87 ( ) Ae (mg) 110 (40) 95 (32) 0.85 ( ) CL R (ml/h) 7,637 (3,723) 6,876 (3,105) 0.91 ( ) a z, terminal elimination rate constant; Ae, amount excreted in urine; AUC 0 t and AUC 0, area under the plasma concentration versus time curve from time zero to the time of the last measurable concentration (t) and to infinity ( ); CI, confidence interval; CL R, renal clearance; C max, maximum plasma concentration; CL/F, oral clearance; t 1/2, terminal elimination half-life; t max, time to C max ; V z /F, terminal phase volume of distribution/bioavailability. b Ranked values of t max were analyzed with the ANOVA model (P 0.001). c Maribavir plus /maribavir alone. FIG. 1. Mean plasma maribavir and VP concentration-time profiles following oral administration of maribavir alone and maribavir plus. vir alone (Table 3). The test for treatment effects for t max was statistically significant (P 0.001). Mean t max values for VP were 2.5 h for maribavir alone and 5.5 h for maribavir plus. Consistent with the concentration-time profile, AUC values were similar between treatments (Fig. 1). Results for the ratio of geometric means of treatments indicated that z for VP was 38% lower for maribavir-plus treatment than for maribavir alone. Adverse events. Maribavir treatment was generally well tolerated (Table 4). With the exception of a report of a headache of moderate intensity, adverse events were of mild intensity. One subject was withdrawn from the study after experiencing vomiting after receiving a single dose of at 400 mg and a single dose of maribavir at 400 mg (sequence 2, treatment period 1). The most-common adverse event was dysgeusia (taste disturbance), reported by nine (47%) and seven (35%) subjects in the maribavir-alone and maribavir-plus- groups, respectively. The onset of dysgeusia was generally within 1 h after dosing, with variable duration (3 min to 23 h), and it was most commonly described as a metallic taste. All events of dysgeusia were considered by the investigator to be of mild intensity and resolved without therapy. Twelve (60%) subjects reported adverse events that the investigator considered to be possibly related to (16 events total) during the maribavir-plus- treatment period. The events included dysgeusia (n 9), nausea (n 3), headache (n 2), abdominal pain (n 1), and vomiting (n 1). No patient had ECG findings that the investigator considered clinically significant at any point during the study. Clinical laboratory, urinalysis, and vital sign evaluations were generally unremarkable. Three subjects had at least one new-onset clinical laboratory value that met a prespecified level of clinical significance: one elevated total bilirubin level (considered re- TABLE 2. Summary of maribavir pharmacokinetic parameters Parameter a Value for: Ratio of geometric means (95% CI) c t max (h) 1.7 (0.8) 1.9 (0.9) Not different b C max ( g/ml) 19.8 (3.9) 21.8 (4.4) 1.10 ( ) z (1/h) (0.042) (0.036) 0.83 ( ) t 1/2 (h) 5.73 (1.78) 6.88 (1.99) 1.20 ( ) AUC 0 t ( g h/ml) 119 (36) 173 (50) 1.46 ( ) AUC 0 ( g h/ml) 126 (41) 194 (64) 1.53 ( ) V z /F (liters) 27.5 (7.6) 21.6 (6.6) 0.78 ( ) CL/F (liters/h) 3.56 (1.30) 2.32 (0.85) 0.65 ( ) Ae (mg) 4.12 (1.47) 9.86 (3.97) 2.38 ( ) CL R (ml/h) 57.2 (18.5) (9.49) 1.63 ( ) a z, terminal elimination rate constant; Ae, amount excreted in urine; AUC 0 t and AUC 0, area under the plasma concentration versus time curve from time zero to the time of the last measurable concentration (t) and to infinity ( ); CI, confidence interval; CL R, renal clearance; C max, maximum plasma concentration; CL/F, oral clearance; t 1/2, terminal elimination half-life; t max, time to C max ; V z /F, terminal phase volume of distribution/bioavailability. b Ranked values of t max were analyzed with the ANOVA model (P ). c Maribavir plus /maribavir alone. TABLE 4. Summary of adverse events for all treated subjects Adverse event Incidence n (%) with treatment of: (n 19) All Treatment related a All (n 20) Treatment related a Dysgeusia 9 (47) 9 (47) 7 (35) 7 (35) Abdominal pain 1 (5) 0 1 (5) 0 Headache (10) 2 (10) Anemia 1 (5) Catheter site edema 1 (5) Furuncle 1 (5) Nausea (5) 0 Genital pruritus, female 1 (11) Vomiting (5) 1 (5) Subjects with 1 adverse event 12 (63) 9 (47) 10 (50) 9 (45) a Treatment related: possibly, probably, or definitely related to study drug, as determined by the investigator.
4 VOL. 52, 2008 EFFECT OF KETOCONAZOLE ON MARIBAVIR PHARMACOKINETICS 1797 lated to sample hemolysis), one elevated eosinophil count (10.2%, in a subject whose baseline value was 9.3%), and one decreased hemoglobin/hematocrit value. Overall, there were no trends suggesting laboratory toxicities associated with maribavir in this study. DISCUSSION This open-label crossover study assessed the effects of on maribavir pharmacokinetics in 19 healthy adults. The results demonstrated that moderately reduced the clearance of both maribavir and VP 44469, its principal metabolite. Based on the assumption that treatment completely inhibited CYP3A4 activity, these results indicate that CYP3A4 is responsible for 35% of the overall clearance of maribavir. The assumption of near-complete inhibition of CYP3A4 by is based on a study using midazolam, a drug metabolized exclusively by CYP3A4, in which reduced the oral clearance of midazolam to about 6% of the baseline value (13). The effects of CYP3A4 inhibition on VP formation and clearance are less straightforward. The rate of VP formation is reduced secondary to CYP3A4 inhibition by as evidenced by lower VP concentrations during the first 8 h after maribavir-plus- administration. VP t 1/2 was also increased, likely secondary to further metabolism via a pathway that may be subject to inhibition by. Although the t 1/2 was increased, it was not accompanied by a significant increase in AUC, suggesting that the overall impact of inhibition of CYP3A4 on VP is offset by a decreased formation of VP and alternate pathways of maribavir elimination. The results of this study also indicate that maribavir is reasonably well tolerated. With the exception of one moderate adverse event (headache), all reported adverse events were mild in intensity, with dysgeusia representing the majority of all adverse events. Vital signs, clinical laboratory tests, and ECG results were unremarkable and did not suggest any abnormalities associated with maribavir administration. These tolerability results are consistent with those observed in other clinical studies using single- or multipledose maribavir (11, 14, 15), in which dysgeusia was the most-notable adverse event. Taste disturbance was reported in 94% of healthy subjects receiving maribavir at 400 mg twice daily for 10 days (11). Similar findings were reported in subjects with renal impairment (14). Determination of the contribution of CYP3A4 to the metabolism and clearance of maribavir is important because there are a number of potential interactions associated with drugs that inhibit this isoenzyme that may be administered concomitantly with maribavir (12). In addition to, examples of inhibitors of this enzyme include other azole antifungal drugs (itraconazole), calcium channel blockers (verapamil and diltiazem), most macrolide antibiotics, HIV protease inhibitors, and grapefruit juice (12). Substrates of this isoenzyme include alprazolam, cyclosporine, HIV protease inhibitors, tacrolimus, terfenadine, and calcium channel blockers (12). Despite near-complete inhibition of CYP3A4 metabolism with concomitant treatment in this study, there was only a moderate change in maribavir pharmacokinetics: the mean C max increased by 10% (95% CI, 1% to 19%), and the mean AUC 0-t increased by 46% (95% CI, 38% to 55%). The CYP3A4 isoenzyme system is estimated to be responsible for approximately 35% of the overall clearance of maribavir. Furthermore, since renal excretion is not a major pathway of elimination, these findings suggest multiple metabolic pathways of elimination for maribavir. These pharmacokinetic findings, in combination with the tolerability in both the maribavir and maribavir-plus- treatment groups, suggest that no dose adjustment of maribavir is necessary when it is coadministered with CYP3A4 inhibitors or substrates. A single oral dose of maribavir at 400 mg was generally well tolerated when administered with or without oral at 400 mg. An earlier study using much higher doses (up to 1,200 mg twice daily) demonstrated a good safety and tolerability profile, with dysgeusia as the most-common adverse event (82%) and diarrhea, nausea, and headache reported in 26% of maribavir-treated subjects (9). The observation that the CYP3A4 isoenzyme is responsible for only about one-third of the overall clearance of maribavir in addition to the established tolerability at higher doses suggest that there is no clinically significant impact on safety from a moderate decrease of elimination with CYP3A4 inhibition as seen in this study. ACKNOWLEDGMENTS We thank Rick Davis for his assistance in drafting the manuscript. This study was funded by ViroPharma Incorporated. This work was conducted at one site: PAREXEL International, Baltimore Clinical Pharmacology Research Unit, Harbor Hospital Center, Baltimore, MD REFERENCES 1. Biron, K. K., R. J. Harvey, S. C. Chamberlain, S. S. Good, A. A. Smith III, M. G. Davis, C. L. Talarico, W. H. Miller, R. Ferris, R. E. Dornsife, S. C. Stanat, J. C. Drach, L. B. Townsend, and G. W. Koszalka Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob. Agents Chemother. 46: Drew, W. L., R. C. Miner, G. I. Marousek, and S. Chou Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J. Clin. Virol. 37: Evers, D. L., G. Komazin, R. G. Ptak, D. Shin, B. T. Emmer, L. B. Townsend, and J. C. Drach Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. Antimicrob. Agents Chemother. 48: Huang, Y. C., J. L. Colaizzi, R. H. Bierman, R. Woestenborghs, and J. Heykants Pharmacokinetics and dose proportionality of in normal volunteers. Antimicrob. Agents Chemother. 30: Kern, E. R., C. B. Hartline, R. J. Rybak, J. C. Drach, L. B. Townsend, K. K. Biron, and D. J. Bidanset Activities of benzimidazole D- and L- ribonucleosides in animal models of cytomegalovirus infections. Antimicrob. Agents Chemother. 48: Koszalka, G. W., N. W. Johnson, S. S. Good, L. Boyd, S. C. Chamberlain, L. B. Townsend, J. C. Drach, and K. K. Biron Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents Chemother. 46: Krosky, P. M., M. C. Baek, and D. M. Coen The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J. Virol. 77: Krosky, P. M., M. C. Baek, W. J. Jahng, I. Barrera, R. J. Harvey, K. K. Biron, D. M. Coen, and P. B. Sethna The human cytomegalovirus UL44 protein is a substrate for the UL97 protein kinase. J. Virol. 77: Lalezari, J. P., J. A. Aberg, L. H. Wang, M. B. Wire, R. Miner, W. Snowden, C. L. Talarico, S. Shaw, M. A. Jacobson, and W. L. Drew Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob. Agents Chemother. 46: Lu, H., and S. Thomas Maribavir (ViroPharma). Curr. Opin. Investig. Drugs 5:
5 1798 GOLDWATER ET AL. ANTIMICROB. AGENTS CHEMOTHER. 11. Ma, J. D., A. N. Nafziger, S. A. Villano, A. Gaedigk, and J. S. Bertino, Jr Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults. Antimicrob. Agents Chemother. 50: Ogu, C. C., and J. L. Maxa Drug interactions due to cytochrome P450. Baylor Univ. Med. Cent. Proc. 13: Olkkola, K. T., J. T. Backman, and P. J. Neuvonen Midazolam should be avoided in patients receiving the systemic antimycotics or itraconazole. Clin. Pharmacol. Ther. 55: Swan, S. K., W. B. Smith, T. C. Marbury, M. Schumacher, C. Dougherty, B. A. Mico, and S. A. Villano Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. J. Clin. Pharmacol. 47: Wang, L. H., R. W. Peck, Y. Yin, J. Allanson, R. Wiggs, and M. B. Wire Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 47: Winston, D., J. van Burik, V. Pullarkat, G. Pananicolaou, R. Vij, E. Vance, G. Alangaden, R. Chemaly, F. Petersen, N. Chao, J. Klein, K. Sprague, C. Dougherty, S. Villano, and M. Boeckh Prophylaxis against cytomegalovirus infections with oral maribavir in allogeneic stem cell transplant recipients: results of a randomized, double-blind, placebo-controlled trial. Blood 108:Abstract 593.
Effect of Ketoconazole on the Pharmacokinetics of Maribavir in Healthy Adults
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2008, p. 1794 1798 Vol. 52, No. 5 0066-4804/08/$08.00 0 doi:10.1128/aac.00951-07 Copyright 2008, American Society for Microbiology. All Rights Reserved. Effect
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationReceived 22 July 2005/Returned for modification 8 September 2005/Accepted 9 January 2006
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Apr. 2006, p. 1130 1135 Vol. 50, No. 4 0066-4804/06/$08.00 0 doi:10.1128/aac.50.4.1130 1135.2006 Copyright 2006, American Society for Microbiology. All Rights Reserved.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationProduct: Cinacalcet hydrochloride Clinical Study Report: Page 2 of 670
Page 2 of 670 2. SYNOPSIS Name of Sponsor: mgen Inc., Thousand Oaks, C Name of Finished Product: Cinacalcet hydrochloride (Sensipar, Mimpara ) Name of ctive Ingredient: cinacalcet (cinacalcet hydrochloride
More informationJohnson & Johnson Pharmaceutical Research & Development, L.L.C.
SYNOPSIS Issue Date: 27 April 2009 Document No.: EDMS-PSDB-9908562:2.0 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient Johnson & Johnson Pharmaceutical Research & Development,
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationResults. Subject Disposition and Demographics Of 37 enrolled subjects, 23 (62.2%) completed the study
Poster 5-20 Effect of Gastric ph on the Bioavailability of in Healthy Subjects James Longstreth, PhD, Marijke H. Adams, PharmD, PhD, 2 Vasi Sperry, PhD, 3 Dan Kajdasz, PhD, 3 Carol R. Reed, MD 3 Longstreth
More informationPrincipal Investigator: Marion, Alan, S, M.D., MDS Pharma Services (US) Inc., 621 Rose Street, PO Box 80837, Lincoln, NE 68502, USA
SYNOPSIS Issue Date: 06 October 2008 Document No.: EDMS-PSDB-8954363:2. Name of Sponsor/Company Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Name of Finished Product Name of Active Ingredient(s)
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationStudy No Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objectives: Study Endpoints: Pharmacokinetics:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationStudy No: LOV OMA-104 Title : Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Statistical Methods
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationClinical Trial Results Summary Study EN
Study Number: EN3288-113 Title of Study: A Double-blind, Dose-Ranging, Pilot Study to Evaluate the Safety, Subjective Effects, and Pharmacokinetics of Oxymorphone Hydrochloride in Healthy Subjects Who
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationSINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF MOXDUO, A DUAL-OPIOID FORMULATION CONTAINING A FIXED RATIO OF MORPHINE AND OXYCODONE
#298 SINGLE-DOSE AND STEADY-STATE PHARMACOKINETICS OF MOXDUO, A DUAL-OPIOID FORMULATION CONTAINING A FIXED RATIO OF MORPHINE AND OXYCODONE LYNN WEBSTER, MD; 1 JOEL OWEN, PHD, RPH; 2 INGER DARLING, PHD;
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationMerck Sharp & Dohme Corp., The Netherlands; Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; Yale University, New Haven, CT, USA;
Pharmacokinetic Interaction Between HCV Protease Inhibitor Boceprevir and Methadone or Buprenorphine/Naloxone in Subjects on Stable Maintenance Therapy Ellen GJ Hulskotte, 1 Hwa-Ping Feng, 2 R Douglas
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationSponsor: Sanofi Drug substance(s): SAR342434
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationComparison of GW (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG Changes (APV10013)
43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) Poster A-1607 Comparison of GW433908 (908) Single Dose and Steady-state Pharmacokinetics (PK): Induction Potential and AAG
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSYNOPSIS. Issue Date: 31 July 2013
SYNOPSIS Issue Date: 31 July 2013 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development, LLC YONDELIS Trabectedin (R279741) Protocol No.: ET743-OVC-1003
More informationStudy Centers: This study was conducted in 2 centers in Italy.
Title of Trial: A randomised, double-blind, placebo-controlled, two-period, two-sequence-crossover interaction study to assess the effect of safinamide on levodopa pharmacokinetics in subjects with Parkinson
More informationLack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacids
Blackwell Science, Ltdxford, UKBJCPBritish Journal of Clinical Pharmacology0306-5251Blackwell Science, 200254riginal Articleseltamivir and antacids lack of kinetic interactionp. Snell et al. Lack of pharmacokinetic
More informationIndividual Study Table Referring to Part of the Dossier. Volume:
Final Report M/100977/21Final Version () 2. SYNOPSIS A Title of Study: A PHASE IIa, RANDOMISED, DOUBLE-BLIND, MULTIPLE DOSE, PLACEBO CONTROLLED, 3 PERIOD CROSS-OVER, ASCENDING DOSE CLINICAL TRIAL TO ASSESS
More informationRonald Goldwater 1 Azra Hussaini
Clin Pharmacokinet (217) 56:83 813 DOI 1.17/s4262-17-536-2 ORIGINAL RESEARCH ARTICLE Comparison of a Novel Formulation of Abiraterone Acetate vs. the Originator Formulation in Healthy Male Subjects: Two
More informationDosage and Administration
SIRTURO product information for healthcare providers 2 WARNINGS: An increased risk of death was seen in the SIRTURO (bedaquiline) treatment group (9/79, 11.4%) compared to the placebo treatment group (2/81,
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationTCP Transl Clin Pharmacol
TCP 2015;23(1):26-30 http://dx.doi.org/10.12793/tcp.2015.23.1.26 Bioequivalence study of Donepezil hydrochloride in healthy Korean volunteers ORIGINAL ARTICLE Yewon Choi 1, Su-jin Rhee 1, In-Jin Jang 1,
More informationActivities of Benzimidazole D- and L-Ribonucleosides in Animal Models of Cytomegalovirus Infections
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, May 2004, p. 1749 1755 Vol. 48, No. 5 0066-4804/04/$08.00 0 DOI: 10.1128/AAC.48.5.1749 1755.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved.
More informationSponsor / Company: Sanofi Drug substance: SAR236553/REGN727 (alirocumab)
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance:
More informationSYNOPSIS. Number of subjects: Planned: 22 Randomized: 23 Treated: 23. Evaluated: Pharmacodynamic: 22 Safety: 23 Pharmacokinetics: 22
SYNOPSIS Title of the study: A randomized, cross-over, open, euglycemic clamp study on the relative bioavailability and activity of 0.6 U/kg insulin glargine and 20 µg lixisenatide, given as on-site mix
More informationPoster O_16. Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA; 2. Lifetree Clinical Research, Salt Lake City, UT, USA
Poster O_16 Lack of PK Interaction Between the HCV Protease Inhibitor MK-5172 and Methadone and Buprenorphine/Naloxone in Subjects on Stable Opiate Maintenance Therapy Iain Fraser, 1 Wendy W. Yeh, 1 Christina
More information2016 BMT Tandem Meetings
ASBMT CIBMTR 2016 BMT Tandem Meetings for Prevention of Cytomegalovirus after Allogeneic Hematopoietic Cell Transplantation in CMV-Seropositive Patients A Randomized, Double-Blind, -Controlled, Parallel-Group
More informationThe study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationCaveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters
Caveat: Validation and Limitations of Phenotyping Methods for Drug Metabolizing Enzymes and Transporters Uwe Fuhr, University Hospital Cologne 1 How to Safeguard that Metrics Reflect E/T Activity? in healthy
More information2.0 Synopsis. ABT-333 M Clinical Study Report R&D/09/956
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-333 Volume: Name of Active Ingredient: Page: Sodium N-{6-[3-tert-butyl-5-(2,4-
More informationTDM. Measurement techniques used to determine cyclosporine level include:
TDM Lecture 15: Cyclosporine. Cyclosporine is a cyclic polypeptide medication with immunosuppressant effect. It has the ability to block the production of interleukin-2 and other cytokines by T-lymphocytes.
More informationCytochrome P450 Drug Interaction Table Flockhart Table
Cytochrome P450 Drug Interaction Table Flockhart Table The table contains lists of drugs in columns under the designation of specific cytochrome P450 isoforms. CYTOCHROME P450 DRUG INTERACTION TABLE A
More informationDrug-Drug Interaction Study of Ketoconazole and Ritonavir-boosted Saquinavir ACCEPTED
AAC Accepts, published online ahead of print on 17 November 2008 Antimicrob. Agents Chemother. doi:10.1128/aac.00769-08 Copyright 2008, American Society for Microbiology and/or the Listed Authors/Institutions.
More informationMipomersen (ISIS ) Page 2 of 1979 Clinical Study Report ISIS CS3
(ISIS 301012) Page 2 of 1979 2 SYNOPSIS ISIS 301012-CS3 synopsis Page 1 Title of Study: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics,
More informationStudy Day 1 Study Days 2 to 9 Sequence 1 Placebo for moxifloxacin Study Days 2 to 8: placebo for pazopanib (placebopaz) 800 mg;
The study listed may include approved non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSponsor: Sanofi Drug substance(s): GZ316455
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor: Sanofi Drug substance(s):
More informationSelected Properties of Daclatasvir
Selected Properties of Daclatasvir Other names Manufacturer Pharmacology / Mechanism of Action Activity Resistance Genotypic Daklinza, BMS-790052 Bristol-Myers Squibb Daclatasvir is a highly potent and
More informationDrug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals
Drug Interactions Between Direct-Acting anti-hcv Antivirals Sofosbuvir and Ledipasvir and HIV Antiretrovirals Polina German, Philip S Pang, Steve West, Lingling Han, Karim Sajwani and Anita Mathias Gilead
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME /GENERIC DRUG NAME: Vfend /Voriconazole
More informationHistamine H 2 -receptor antagonists have no clinically significant effect on the steady-state pharmacokinetics of voriconazole
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology1365-2125Blackwell Publishing 200356S15155Original ArticleEffects of cimetidine and ranitidine on voriconazole pharmacokineticsl.
More informationBRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS
BRINCIDOFOVIR WAS USED TO SUCCESSFULLY TREAT ADENOVIRUS INFECTIONS IN SOLID ORGAN TRANSPLANT RECIPIENTS AND OTHER IMMUNOCOMPROMISED PATIENTS Diana F. Florescu, MD 1, Michael S. Grimley, MD 2, Genovefa
More informationThe clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.
The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. Please note that the results reported in any single trial may not reflect the overall
More informationReceived 21 December 2012; returned 4 January 2013; revised 19 February 2013; accepted 23 February 2013
J Antimicrob Chemother 013; 68: 1901 1909 doi:10.1093/jac/dkt097 Advance Access publication 3 April 013 Safety, tolerability and pharmacokinetics of repeat dosing of the antibiotic GSK133, a peptide deformylase
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of
More informationPFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
Public Disclosure Synopsis Protocol A7772 September 25 Final PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
More informationGSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTo assess safety profiles: significant laboratory changes and adverse events (AEs).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationJieon Lee 1, AnHye Kim 1, Kyung-Sang Yu 1, Jae-Yong Chung 2, Sung-Vin Yim 3 and Bo-Hyung Kim 3 * 1 ORIGINAL ARTICLE
TCP 2015;23(2):49-53 http://dx.doi.org/10.12793/tcp.2015.23.2.49 Pharmacokinetics and bioequivalence of two different 20 mg olmesartan tablets: A randomized, single-dose, two-period crossover study in
More informationClinical Study Synopsis for Public Disclosure
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis - which is part of the clinical
More informationClinical Trials A Practical Guide to Design, Analysis, and Reporting
Clinical Trials A Practical Guide to Design, Analysis, and Reporting Duolao Wang, PhD Ameet Bakhai, MBBS, MRCP Statistician Cardiologist Clinical Trials A Practical Guide to Design, Analysis, and Reporting
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen This full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/14779
More informationA Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl Citrate
Vol. 26 No. 2 August 2003 Journal of Pain and Symptom Management 743 Original Article A Pharmacokinetic Study to Compare Two Simultaneous 400 µg Doses with a Single 800 µg Dose of Oral Transmucosal Fentanyl
More informationClinical Trial Results Database Page 1
Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Corporation Generic Drug Name Therapeutic Area of Trial Major Depressive Disorder (MDD) Approved Indication Treatment of major depressive
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Prevymis TM GENERIC NAME Letermovir MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL November 9, 2017 PRODUCT LAUNCH DATE TBD REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of new
More informationSYNOPSIS. Publications No publications at the time of writing this report.
Drug product: TOPROL-XL Drug substance(s): Metoprolol succinate Study code: D4020C00033 (307A) Date: 8 February 2006 SYNOPSIS Dose Ranging, Safety and Tolerability of TOPROL-XL (metoprolol succinate) Extended-release
More informationReferring to Part IV of the Dossier
2. SYNOPSIS Name of Company: Mundipharma Research Limited Name of Finished Product: FlutiForm Name of Active Ingredient: Fluticasone propionate / Formoterol fumarate INDIVIDUAL STUDY TABLE Referring to
More informationSYNOPSIS. Study centre(s) The study was performed in Denmark, Norway and Sweden at 20 sites.
Drug substance(s): AZD0837 Edition No.: 1 Study code: D1250C00007 Date: 22 May, 2006 SYNOPSIS (For national authority use only) A Controlled, Randomised, Parallel, Multicentre Study to Assess Safety and
More informationIntroduction to. Pharmacokinetics. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Introduction to 1 Pharmacokinetics University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 2 Learning objectives Understand compartment models and how they effects
More informationThe pharmacokinetics and safety of intravenous voriconazole a novel wide-spectrum antifungal agent
Blackwell Science, LtdOxford, UKBCPBritish Journal of Clinical Pharmacology1365-2125Blackwell Publishing 2356S129Original ArticlePharmacokinetics and safety of intravenous voriconazolel. Purkins et al.
More informationKimberly Adkison, 1 Lesley Kahl, 1 Elizabeth Blair, 1 Kostas Angelis, 2 Herta Crauwels, 3 Maria Nascimento, 1 Michael Aboud 1
Pharmacokinetics of Dolutegravir and Rilpivirine After Switching to the Two-Drug Regimen From an Efavirenz- or Nevirapine- Based Antiretroviral Regimen: SWORD-1 & -2 Pooled PK Analysis Kimberly Adkison,
More informationClinical Study Report AI Final 28 Feb Volume: Page:
Study Design, Continued Electrocardiogram (ECG) and vital sign assessments were done at select times during the study. Blood and urine samples for clinical laboratory evaluations were collected at specified
More informationBrand Name: Xofluza. Generic Name: Baloxavir marboxil. Manufacturer 1 : Genetech USA, INC
Brand Name: Xofluza Generic Name: Baloxavir marboxil Manufacturer 1 : Genetech USA, INC Drug Class 2,3,4,5 : Anti-infective agent; Antiviral Agent; Endonuclease inhibitor Uses: Labeled Uses 1,2,3,4,5 :
More informationSingle-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men
Citation: Clin Transl Sci (2017) 10, 480 486; C 2017 ASCPT. All rights reserved doi:10.1111/cts.12482 ARTICLE Single-Dose and Multiple-Dose Pharmacokinetics of Vaniprevir in Healthy Men LCaro 1, J de Hoon
More informationEffect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects
Effect of Daclatasvir/Asunaprevir/Beclabuvir in Fixed-dose Combination on the Pharmacokinetics of CYP450/Transporter Substrates In Healthy Subjects Xiaolu Tao 1, Karen Sims 1, Yi-Ting Chang 1, Jignasa
More informationProduct: Denosumab (AMG 162) Clinical Study Report: month Primary Analysis Date: 21 November 2016 Page 1
Date: 21 November 2016 Page 1 2. SYNOPSIS Name of Sponsor: Amgen Inc., Thousand Oaks, CA, USA Name of Finished Product: Prolia Name of Active Ingredient: denosumab Title of Study: Randomized, Double-blind,
More informationErik Mogalian, Polina German, Chris Yang, Lisa Moorehead, Diana Brainard, John McNally, Jennifer Cuvin, Anita Mathias
Evaluation of Transporter and Cytochrome P450-Mediated Drug-Drug Interactions Between Pan-Genotypic HCV NS5A Inhibitor GS-5816 and Phenotypic Probe Drugs Erik Mogalian, Polina German, Chris Yang, Lisa
More informationPrincipal Investigator and Study Center: F. Nobuoka, MD Ageo Medical Clinic, 3133 Haraichi, Ageo City, Saitama , Japan
Page 1 APPENDIX 9: ZRHM-PK-05-JP CLINICAL STUDY SUMMARY The study was conducted in Japan from August to November 2013. Principles as defined in International Conference on Harmonization (ICH) Good Clinical
More informationElements for a Public Summary. Overview of disease epidemiology
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Gout i Gout has a worldwide distribution. In the United Kingdom from 2000 to 2007, the estimated occurrence of gout is 5.9% in
More informationRelative Bioavailability and Bioequivalence of Brivaracetam 10 mg/ml Oral Solution and 50-mg Film-Coated Tablet
Brief Report Relative Bioavailability and Bioequivalence of Brivaracetam 10 mg/ml Oral Solution and 50-mg Film-Coated Tablet Clinical Pharmacology in Drug Development 2017, 6(3) 313 317 C 2016, The American
More informationImmediate-release Hydrocodone/Acetaminophen M Abbreviated Clinical Study Report R&D/08/1020
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Hydrocodone Bitartrate- Acetaminophen (NORCO ) Name of
More informationPharmacokinetics for Physicians. Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne
Pharmacokinetics for Physicians Assoc Prof. Noel E. Cranswick Clinical Pharmacologist Royal Children s Hospital Melbourne The Important Therapeutic Questions What drug? What dose? How long? Drug Dosage
More information090177e182b31c5d\0.1\Draft\Versioned On:16-Dec :12
MAH: / Product: IBU/PSE Protocol Number EudraCT number (if applicable) Trial report number PMID / D.O.I. (if applicable) Date of trial Is the trial Trial design Background for conducting the trial Participants
More informationMutations in the Human Cytomegalovirus UL27 Gene That Confer Resistance to Maribavir
JOURNAL OF VIROLOGY, July 2004, p. 7124 7130 Vol. 78, No. 13 0022-538X/04/$08.00 0 DOI: 10.1128/JVI.78.13.7124 7130.2004 Copyright 2004, American Society for Microbiology. All Rights Reserved. Mutations
More informationSummary ID# Clinical Study Summary: Study B4Z-MC-LYBX
CT Registry ID#7068 Page 1 Summary ID# 7068 Clinical Study Summary: Study B4Z-MC-LYBX A Randomized, Double-Blind Comparison of Hydrochloride and Placebo in Child and Adolescent Outpatients with Attention-
More informationEffects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers
British Journal of Clinical Pharmacology DOI:10.1111/j.1365-2125.2011.03989.x Effects of fesoterodine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers Bimal Malhotra, 1 Christine
More informationReports of efficacy and safety studies of primary immunodeficiency
2. SYNOPSIS TITLE OF STUDY: Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of IGIV3I GRIFOLS [Immune Globulin Intravenous (Human)] for Replacement Therapy in Primary Immunodeficiency
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Vicodin CR Name of Active Ingredient: Page: Hydrocodone/Acetaminophen
More informationSponsor Novartis. Generic Drug Name Vildagliptin/Metformin. Therapeutic Area of Trial Type 2 diabetes. Approved Indication Type 2 diabetes
Clinical Trial Results Database Page 1 Sponsor Novartis Generic Drug Name Vildagliptin/Metformin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Study Number CLMF237A2309
More informationThese results are supplied for informational purposes only.
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationReceived 9 March 2009/Returned for modification 23 June 2009/Accepted 3 August 2009
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2009, p. 4885 4890 Vol. 53, No. 11 0066-4804/09/$12.00 doi:10.1128/aac.00319-09 Copyright 2009, American Society for Microbiology. All Rights Reserved. Effect
More informationDr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Bioavailability is a measurement of the rate and extent of drug that reaches the systemic circulation from a drug product or a dosage form. There are two different types
More informationHydrocodone/Acetaminophen Extended-Release Tablets M Clinical Study Report R&D/09/1109
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: ABT-712 Volume: Hydrocodone/Acetaminophen Extended-Release Name
More information